Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2′-O-methyl-RNA

Journal of Pharmaceutical Sciences

Volumn 98, Issue 5, 2009, Pages 1765-1774

  Beisner, Julia ^a   Dong, Meng ^a   Taetz, Sebastian ^c   Piotrowska, Kamilla ^a   Kleideiter, Elke ^a   Friedel, Godehard ^b   Schaefer, Ulrich ^c   Lehr, Claus Michael ^c   Klotz, Ulrich ^a   Mürdter, Thomas E ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Schillerhöhe Specialist Hospital   (Germany)

Author keywords

2 O methyl RNA; Antisense; Cancer; Inhibition; Oligonucleotide delivery; Oligonucleotides; Telomerase; Transfection

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 2' METHYL RNA; ANTISENSE OLIGONUCLEOTIDE; FUGENE; FUGENE 6; LIPOSOME; MATRA; MATRA A; MEGAFECTIN; MEGAFECTIN 60; SUPERFECT; TELOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER;

EID: 65949122738     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21553     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics. CA Cancer J Clin 57:43-66.
2. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW. 1995. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87:895-902.
3. Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore MA, Dmitrovsky E. 1997. High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 89:1609-1615.
4. Pitts AE, Corey DR. 1998. Inhibition of human telomerase by 2′-O-methyl-RNA. Proc Natl Acad Sci USA 95:11549-11554.
5. Piotrowska K, Kleideiter E, Mürdter TE, Taetz S, Baldes C, Schaefer U, Lehr CM, Klotz U. 2005. Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Lab Invest 85:1565-1569.
6. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK. 1992. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033.
7. Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A. 1993. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 197:818-825.
8. Simberg D, Weisman S, Talmon Y, Barenholz Y. 2004. DOTAP (and other cationic lipids): Chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 21:257-317.
9. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. 1997. Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15:647-652.
10. Hong K, Zheng W, Baker A, Papahadjopoulos D. 1997. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett 400:233-237.
11. Liu Y, Mounkes LC, Liggitt HD, Brown CS, Solodin I, Heath TD, Debs RJ. 1997. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 15:167-173.
12. Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, Gao B, Girard L, Minna JD, Roth JA, Kundra V, Ji L. 2006. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 66:9682-9690.
13. Ryschich E, Huszty G, Wentzensen N, Schmidt E, Knaebel HP, Encke J, Märten A, Büchler MW, Schmidt J. 2007. Effect of Flt3 ligand gene transfer in experimental pancreatic cancer. Int J Colorectal Dis 22:215-223.
14. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, Gänsbacher B, Plank C. 2002. Magnetofection: Enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 9:102-109.
15. Ross PC, Hui SW. 1999. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Ther 6:651-659.
16. Jacobsen LB, Calvin SA, Colvin KE, Wright M. 2004. FuGENE 6 Transfection Reagent: The gentle power. Methods 33:104-112.
17. Tao M, Miyano-Kurosaki N, Takai K, Takaku H. 1999. Specific inhibition of human telomerase activity by transfection reagent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells. FEBS Lett 454:312-316.
18. Tamura Y, Tao M, Miyano-Kurosaki N, Takai K, Takaku H. 2000. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells. Antisense Nucleic Acid Drug Dev 10:87-96.
19. Bielinska A, Kukowska-Latallo JF, Johnson J, Tomalia DA, Baker JR Jr. 1996. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 24:2176-2182.
20. Coulis CM, Lee C, Nardone V, Prokipcak RD. 2000. Inhibition of c-myc expression in cells by targeting an RNA-protein interaction using antisense oligonucleotides. Mol Pharmacol 57:485-494.
21. Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, Fujibayashi Y, Konishi J, Brechbiel MW. 2001. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 7:3606-3612.
22. Hollins AJ, Benboubetra M, Omidi Y, Zinselmeyer BH, Schatzlein AG, Uchegbu IF, Akhtar S. 2004. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res 21:458-466.
23. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. 2005. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 12:1544-1550.
24. Tang MX, Redemann CT, Szoka FC Jr. 1996. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem 7:703-714.
25. Krötz F, de Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, Plank C. 2003. Magnetofection - A highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 7:700-710.
26. Krötz F, Sohn HY, Gloe T, Plank C, Pohl U. 2003. Magnetofection potentiates gene delivery to cultured endothelial cells. J Vasc Res 40:425-434.
27. Gersting SW, Schillinger U, Lausier J, Nicklaus P, Rudolph C, Plank C, Reinhardt D, Rosenecker J. 2004. Gene delivery to respiratory epithelial cells by magnetofection. J Gene Med 6:913-922.
28. Holt SE, Wright WE, Shay JW. 1996. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 16:2932-2939.